Choosing between endocrine therapy and chemotherapy - Or is there a role for combination therapy?

Breast Cancer Research and Treatment

Volumn 75, Issue SUPPL. 1, 2002, Pages

  Forbes, John F ^a   Gradishar, William J ^b   Ravdin, Peter M ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast cancer; Chemotherapy; Combination therapy; Endocrine therapy; Estrogen receptor; Tamoxifen

Indexed keywords

ANTIESTROGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

AGE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; HORMONAL THERAPY; HUMAN; PATIENT CARE; PRIORITY JOURNAL;

EID: 0036777550     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1020365800921     Document Type: Conference Paper

References (27)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Tamoxifen for early breast cancer: An overview of the randomised trials
3. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer
4. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer
5. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age
6. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes
7. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle
8. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
9. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients
10. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
11. Tamoxifen - The treatment of choice. Why look for alternatives?
12. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study
13. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
14. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer
15. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk, node-negative patients: First results of Intergroup trial 0102
16. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer?
17. Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin?: First results of IBCSG trial VIII
18. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B- 15
19. Taxanes in the adjuvant treatment of breast cancer: Why not yet?
20. Adjuvant chemotherapy: Taxanes - The "pro" position
21. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes
22. Ovarian ablation in early breast cancer: Overview of the randomised trials
23. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials
24. Duration of adjuvant hormonal treatment
25. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women
26. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
27. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer